Non-Small Cell Adenocarcinoma (NSCLC) is a type of lung cancer that originates in the cells lining the airways of the lungs. It’s the most common type of lung cancer, accounting for about 85% of all cases. NSCLC is divided into different subtypes, with adenocarcinoma being one of them. Adenocarcinoma typically starts in the cells that produce mucus in the lungs.
The Rife Digital Professional V3 utilizes frequencies to target specific pathogens or conditions in the body, including cancer. The frequency set provided below is tailored to target Non-Small-Cell Lung Cancer, including adenocarcinoma.
Here’s how it may assist with treatment:
Frequency Targeting: The Rife machine emits electromagnetic frequencies that resonate with and disrupt the cellular structure of the cancer cells. Each frequency in the group below is purportedly aimed at interfering with the growth and proliferation of NSCLC cells.
Carcinoma, Non-Small-Cell Lung [Cancer]: 0.07, 0.12, 0.6, 0.8, 2.5, 22.5, 72.5, 434.39, 739.1, 905.31
Cellular Disruption: The frequencies interfere with the cancer cells’ ability to replicate and spread, potentially leading to their destruction.
Immune Response: Rife therapy stimulates the body’s immune system to better recognize and attack cancer cells.
Complementary Treatment: It’s important to note that Rife therapy is often considered an alternative or complementary treatment, and it’s typically used alongside conventional cancer treatments. Helps to extend the time to use the machine and assure it is all gone.
Regarding the treatment process:
Duration: Treatment with the Rife machine can take 3-6 months. This duration allows for consistent exposure to the frequencies to maximize their potential effect on the cancer cells.
Usage: The device typically requires overnight sessions. Patients may need to use velcro straps to secure the electrodes or straps to their feet, ensuring that the frequencies are effectively transmitted through the body.
